Cargando…

Using a competitive counterflow assay to identify novel cationic substrates of OATP1B1 and OATP1B3

OATP1B1 and OATP1B3 are two drug transporters that mediate the uptake of multiple endo- and xenobiotics, including many drugs, into human hepatocytes. Numerous inhibitors have been identified, and for some of them, it is not clear whether they are also substrates. Historically radiolabeled substrate...

Descripción completa

Detalles Bibliográficos
Autores principales: Schnegelberger, Regina D., Steiert, Brianna, Sandoval, Philip J., Hagenbuch, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493024/
https://www.ncbi.nlm.nih.gov/pubmed/36160869
http://dx.doi.org/10.3389/fphys.2022.969363
_version_ 1784793606301679616
author Schnegelberger, Regina D.
Steiert, Brianna
Sandoval, Philip J.
Hagenbuch, Bruno
author_facet Schnegelberger, Regina D.
Steiert, Brianna
Sandoval, Philip J.
Hagenbuch, Bruno
author_sort Schnegelberger, Regina D.
collection PubMed
description OATP1B1 and OATP1B3 are two drug transporters that mediate the uptake of multiple endo- and xenobiotics, including many drugs, into human hepatocytes. Numerous inhibitors have been identified, and for some of them, it is not clear whether they are also substrates. Historically radiolabeled substrates or LC-MS/MS methods were needed to test for transported substrates, both of which can be limiting in time and money. However, the competitive counterflow (CCF) assay originally described for OCT2 and, more recently, for OCT1, OATP2B1, and OATP1A2 does not require radiolabeled substrates or LC-MS/MS methods and, as a result, is a more cost-effective approach to identifying substrates of multidrug transporters. We used a CCF assay based on the stimulated efflux of the common model substrate estradiol-17β-glucuronide (E17βG) and tested 30 compounds for OATP1B1- and OATP1B3-mediated transport. Chinese Hamster Ovary (CHO) cells stably expressing OATP1B1 or OATP1B3 were preloaded with 10 nM [(3)H]-estradiol-17β-glucuronide. After the addition of known substrates like unlabeled estradiol-17β-glucuronide, estrone-3-sulfate, bromosulfophthalein, protoporphyrin X, rifampicin, and taurocholate to the outside of the preloaded CHO cells, we observed efflux of [(3)H]-estradiol-17β-glucuronide due to exchange with the added compounds. Of the tested 30 compounds, some organic cation transporter substrates like diphenhydramine, metformin, and salbutamol did not induce [(3)H]-estradiol-17β-glucuronide efflux, indicating that the two OATPs do not transport them. However, 22 (for OATP1B1) and 16 (for OATP1B3) of the tested compounds resulted in [(3)H]-estradiol-17β-glucuronide efflux, suggesting that they are OATP substrates. Among these compounds, we further tested clarithromycin, indomethacin, reserpine, and verapamil and confirmed that they are substrates of the two OATPs. These results demonstrate that the substrate spectrum of the well-characterized organic anion transporting polypeptides includes several organic cations. Furthermore, as for other drug uptake transporters, the CCF assay is an easy-to-use screening tool to identify novel OATP substrates.
format Online
Article
Text
id pubmed-9493024
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94930242022-09-23 Using a competitive counterflow assay to identify novel cationic substrates of OATP1B1 and OATP1B3 Schnegelberger, Regina D. Steiert, Brianna Sandoval, Philip J. Hagenbuch, Bruno Front Physiol Physiology OATP1B1 and OATP1B3 are two drug transporters that mediate the uptake of multiple endo- and xenobiotics, including many drugs, into human hepatocytes. Numerous inhibitors have been identified, and for some of them, it is not clear whether they are also substrates. Historically radiolabeled substrates or LC-MS/MS methods were needed to test for transported substrates, both of which can be limiting in time and money. However, the competitive counterflow (CCF) assay originally described for OCT2 and, more recently, for OCT1, OATP2B1, and OATP1A2 does not require radiolabeled substrates or LC-MS/MS methods and, as a result, is a more cost-effective approach to identifying substrates of multidrug transporters. We used a CCF assay based on the stimulated efflux of the common model substrate estradiol-17β-glucuronide (E17βG) and tested 30 compounds for OATP1B1- and OATP1B3-mediated transport. Chinese Hamster Ovary (CHO) cells stably expressing OATP1B1 or OATP1B3 were preloaded with 10 nM [(3)H]-estradiol-17β-glucuronide. After the addition of known substrates like unlabeled estradiol-17β-glucuronide, estrone-3-sulfate, bromosulfophthalein, protoporphyrin X, rifampicin, and taurocholate to the outside of the preloaded CHO cells, we observed efflux of [(3)H]-estradiol-17β-glucuronide due to exchange with the added compounds. Of the tested 30 compounds, some organic cation transporter substrates like diphenhydramine, metformin, and salbutamol did not induce [(3)H]-estradiol-17β-glucuronide efflux, indicating that the two OATPs do not transport them. However, 22 (for OATP1B1) and 16 (for OATP1B3) of the tested compounds resulted in [(3)H]-estradiol-17β-glucuronide efflux, suggesting that they are OATP substrates. Among these compounds, we further tested clarithromycin, indomethacin, reserpine, and verapamil and confirmed that they are substrates of the two OATPs. These results demonstrate that the substrate spectrum of the well-characterized organic anion transporting polypeptides includes several organic cations. Furthermore, as for other drug uptake transporters, the CCF assay is an easy-to-use screening tool to identify novel OATP substrates. Frontiers Media S.A. 2022-09-08 /pmc/articles/PMC9493024/ /pubmed/36160869 http://dx.doi.org/10.3389/fphys.2022.969363 Text en Copyright © 2022 Schnegelberger, Steiert, Sandoval and Hagenbuch. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Schnegelberger, Regina D.
Steiert, Brianna
Sandoval, Philip J.
Hagenbuch, Bruno
Using a competitive counterflow assay to identify novel cationic substrates of OATP1B1 and OATP1B3
title Using a competitive counterflow assay to identify novel cationic substrates of OATP1B1 and OATP1B3
title_full Using a competitive counterflow assay to identify novel cationic substrates of OATP1B1 and OATP1B3
title_fullStr Using a competitive counterflow assay to identify novel cationic substrates of OATP1B1 and OATP1B3
title_full_unstemmed Using a competitive counterflow assay to identify novel cationic substrates of OATP1B1 and OATP1B3
title_short Using a competitive counterflow assay to identify novel cationic substrates of OATP1B1 and OATP1B3
title_sort using a competitive counterflow assay to identify novel cationic substrates of oatp1b1 and oatp1b3
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493024/
https://www.ncbi.nlm.nih.gov/pubmed/36160869
http://dx.doi.org/10.3389/fphys.2022.969363
work_keys_str_mv AT schnegelbergerreginad usingacompetitivecounterflowassaytoidentifynovelcationicsubstratesofoatp1b1andoatp1b3
AT steiertbrianna usingacompetitivecounterflowassaytoidentifynovelcationicsubstratesofoatp1b1andoatp1b3
AT sandovalphilipj usingacompetitivecounterflowassaytoidentifynovelcationicsubstratesofoatp1b1andoatp1b3
AT hagenbuchbruno usingacompetitivecounterflowassaytoidentifynovelcationicsubstratesofoatp1b1andoatp1b3